CYP19A1 and breast carcinoma: First-line treatment for advanced breast cancer of the estrogen receptor (ER)-driven subtype predominantly involves endocrine therapies, such as selective estrogen receptor modulator (SERM), selective estrogen receptor down-regulator (SERD) or aromatase inhibitors (AIs).